title: Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
authors.forename: Mark
authors.initials: M
authors.lastname: Greener
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing / Q000592:standards* / Q000639:trends; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D007783:Lactones; D013450:Sulfones; C116926:rofecoxib
references.citation: Br J Clin Pharmacol. 1999 Oct;48(4):623-7
references.pmid: 10583035
references.citation: J Health Econ. 2003 Mar;22(2):151-85
references.pmid: 12606142
references.citation: Nat Rev Drug Discov. 2005 Jan;4(1):5-7
references.pmid: 15690595
references.citation: N Engl J Med. 2004 Oct 21;351(17):1707-9
references.pmid: 15470193
references.citation: Nat Rev Drug Discov. 2004 Apr;3(4):360-4
references.pmid: 15060531